Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to be driven by autoimmune processes. Because vitiligo affects patients’ appearance, the disease burden is high. Until 2022, no therapies were approved to treat it; topical corticosteroids or other immunomodulators alone or in combination with narrow-band UVB to induce repigmentation were the mainstay treatments for vitiligo patients. However, these treatments offer only modest clinical benefit and can have troublesome side effects. The FDA’s July 2022 approval of Incyte’s Opzelura (topical ruxolitinib) gives patients the first approved pharmacological treatment for repigmentation in vitiligo. The FDA approved Opzelura cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 or older. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for vitiligo.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed vitiligo patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed vitiligo patients?
- How has Opzelura been integrated into the treatment algorithm, and what is its source of business?
- What percentage of vitiligo patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of vitiligo patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Content highlights
Publication date: January 2025
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Opzelura, key topical corticosteroids, and calcineurin inhibitors
Key analyses
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow charts
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
